

Tuberculosis profile: Philippines

Population 2021: 114 million

Estimates of TB burden*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	741 000 (401 000-1 180 000)	650 (352-1040)
HIV-positive TB incidence	14 000 (5 800-27 000)	13 (5.1-23)
MDR/RR-TB incidence**	21 000 (8 300-34 000)	19 (7.3-30)
HIV-negative TB mortality	60 000 (53 000-67 000)	52 (46-59)
HIV-positive TB mortality	810 (710-910)	0.71 (0.62-0.8)

Estimated proportion of TB cases with MDR/RR-TB*, 2021

New cases	1.5% (0.97-2.1)
Previously treated cases	26% (25-27)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2021	43% (27-80)
TB patients facing catastrophic total costs, 2017	42% (39-46)
TB case fatality ratio (estimated mortality/estimated incidence), 2021	9% (5-14)

TB case notifications, 2021

Total new and relapse	321 564
- % tested with rapid diagnostics at time of diagnosis	65%
- % with known HIV status	34%
- % pulmonary	98%
- % bacteriologically confirmed ^	44%
- % children aged 0-14 years	7%
- % women (aged ≥15 years)	31%
- % men (aged ≥15 years)	62%
Total cases notified	328 497

TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	1 350	1.2%
- on antiretroviral therapy	1 349	100%

Drug-resistant TB care**, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	89%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	93%
Laboratory-confirmed cases - MDR/RR-TB ^^	7 589
Patients started on treatment - MDR/RR-TB ^^	5 946
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	62
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	62
MDR/RR-TB cases tested for resistance to any fluoroquinolone	1 302

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	76%	270 987
Previously treated cases, excluding relapse, registered in 2020	68%	6 011
HIV-positive TB cases registered in 2020	81%	991
MDR/RR-TB cases started on second-line treatment in 2019	73%	5 641
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019	74%	259


TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	45%
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	5.5% (5.1-6)


Funding for TB

Funding for TB, 2021 (US\$ millions)	99
- % domestic funding	40%
- % international funding	60%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2021



Cases attributable to five risk factors, 2021



Funding for TB (US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
** RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
^ Calculated for pulmonary cases only
^^ Includes cases with unknown previous TB treatment history
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

Generated 2022-11-28 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)